Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome
Spremljeno u:
Glavni autori: | Xiaoman Du, MD (Autor), Yudi Chen, MD (Autor), Jianmin Chang, MD (Autor), Xuelin Sun, MD, PhD (Autor), Yue Zhang, MS (Autor), Meng Zhang, BM (Autor), Marcus Maurer, MD, PhD (Autor), Yanming Li, MD (Autor), Zuotao Zhao, MD, PhD (Autor), Xunliang Tong, MD, PhD (Autor) |
---|---|
Format: | Knjiga |
Izdano: |
Elsevier,
2022-11-01T00:00:00Z.
|
Teme: | |
Online pristup: | Connect to this object online. |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Slični predmeti
-
Exacerbation of IgA nephropathy in a patient receiving dupilumab
od: Masako Yamamoto, MD, i dr.
Izdano: (2022) -
The dermatologic and histologic spectrum of hypereosinophilic syndrome
od: Calista Long, BS, i dr.
Izdano: (2023) -
Vitiligo during dupilumab therapy
od: Vincenzo Picone, MD, i dr.
Izdano: (2023) -
Onychodystrophy associated with dupilumab therapy for atopic dermatitis
od: Amanda E. Zubek, MD, PhD, i dr.
Izdano: (2021) -
Treatment of lichen sclerosus and hypertrophic scars with dupilumab
od: Danielle M. Peterson, MD, i dr.
Izdano: (2022)